TY  - JOUR
AU  - de la Cruz-Merino, Luis
AU  - Gion, María
AU  - Cruz-Jurado, Josefina
AU  - Quiroga, Vanesa
AU  - Andrés, Raquel
AU  - Moreno, Fernando
AU  - Alonso-Romero, Jose L
AU  - Ramos, Manuel
AU  - Holgado, Esther
AU  - Cortés, Javier
AU  - López-Miranda, Elena
AU  - Henao-Carrasco, Fernando
AU  - Palazón-Carrión, Natalia
AU  - Rodríguez, Luz M
AU  - Ceballos, Isaac
AU  - Casas, Maribel
AU  - Benito, Sara
AU  - Chiesa, Massimo
AU  - Bezares, Susana
AU  - Caballero, Rosalia
AU  - Jiménez-Cortegana, Carlos
AU  - Sánchez-Margalet, Víctor
AU  - Rojo, Federico
PY  - 2021
DO  - 10.3390/cancers13215432
SN  - 2072-6694
UR  - https://hdl.handle.net/10668/24740
T2  - Cancers
AB  - The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab...
LA  - en
KW  - MDSCs
KW  - PD-L1
KW  - TILs
KW  - biomarkers
KW  - breast cancer
KW  - immunotherapy
KW  - pembrolizumab
KW  - phase II
KW  - triple-negative
TI  - Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.
TY  - research article
VL  - 13
ER  -